The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trialAngela Huttner, Claire‐Anne Siegrist, Markus Eickmann et al.|The Lancet Infectious Diseases|2015Cited by 278
Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker studyEleonora Vianello, Sylvia Rothenberger, Patrícia Gonzalez‐Dias et al.|The Lancet Microbe|2021Cited by 13
Global blood miRNA profiling unravels early signatures of immunogenicity of Ebola vaccine rVSVΔG-ZEBOV-GPEleonora Vianello, Helder I. Nakaya, Josefine Persson et al.|iScience|2023Cited by 7